The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) . Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease . In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches. © 2009 Springer Science+Business Media, LLC.
Alatrash, G., & Molldrem, J. J. (2010). Immunotherapy of AML. Cancer Treatment and Research. https://doi.org/10.1007/978-0-387-69259-3_14